Multiparametric Imaging for Therapy Response to Cytotoxic & Cytostatic Agents in Xenograft Mice

Natalie J. Serkova¹, Erica L. Pierce², Kendra M. Hasebroock¹, Andrea L. Merz¹, Todd M. Pitts², Gail Eckhardt²

The goal of this study was to establish functional (DW-MRI) and metabolic (PET and MRS) imaging end-points for therapy response to classic cytotoxic and novel cytostatic agents. A mouse colorecral cancer model was chosen to evaluate therapy response to a novel IGF1R tyrosine kinase inhibitor (cytostatic) and to irinotecan (cytotoxic). Specific multiparametric imaging end-points for therapeutic responses to a novel cytostatic STI (include ecreased glucose and choline uptake by PET as well as decreased lactate and choline metabolism by MRS). In contrast, cytotoxic effects of a chemotherapeutic agent result in increased ADC by DW-MRI and increased phospholipid and nucleotide breakdown.